Paul Wotton Biography and Net Worth

Director of Vericel

Dr. Paul Wotton is Chief Executive Officer and a member of the board of directors of Obsidian Therapeutics, Inc. – a position he has held since April 2019. Previously, Dr. Wotton was the founding President and Chief Executive Officer of Sigilon Therapeutics, Inc., a privately held cell therapeutics company, which began in May 2016. Prior to that, Dr. Wotton served as the President, Chief Executive Officer and a member of the board of directors of Ocata Therapeutics, Inc. until its acquisition by Astellas Pharma US, Inc. in February 2016. Prior to Ocata, he served as President and Chief Executive Officer and as a member of the board of directors of Antares Pharma, Inc., as Chief Executive Officer of Topigen Pharmaceuticals, and as the Global Head of Business Development of SkyePharma PLC. Earlier in his career, Dr. Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton serves as Chairman of the board of directors of Cynata Therapeutics Limited and is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. In 2014, Dr. Wotton was named Ernst & Young Entrepreneur of the Year for Life Sciences, New Jersey. Dr. Wotton received his Bachelor’s in Pharmacy, with honors, from University College London, his Ph.D. in pharmaceutical sciences from the University of Nottingham, and his MBA from Kingston Business School.

What is Paul K. Wotton's net worth?: The estimated net worth of Paul K. Wotton is at least $1.22 million as of December 4th, 2024. Dr. Wotton owns 27,402 shares of Vericel stock worth more than $1,219,389 as of March 28th. This net worth estimate does not reflect any other investments that Dr. Wotton may own. Learn More about Paul K. Wotton's net worth.
How do I contact Paul K. Wotton?: The corporate mailing address for Dr. Wotton and other Vericel executives is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. Vericel can also be reached via phone at (617) 588-5555 and via email at ir@vcel.com. Learn More on Paul K. Wotton's contact information.
Has Paul K. Wotton been buying or selling shares of Vericel?: Paul K. Wotton has not been actively trading shares of Vericel during the last ninety days. Most recently, Paul K. Wotton sold 2,600 shares of the business's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $58.72, for a transaction totalling $152,672.00. Following the completion of the sale, the director now directly owns 27,402 shares of the company's stock, valued at $1,609,045.44. Learn More on Paul K. Wotton's trading history.
Who are Vericel's active insiders?: Vericel's insider roster includes Dominick Colangelo (President & CEO), Sean Flynn (VP), Steven Gilman (Director), Michael Halpin (COO), Jonathan Hopper (Insider), Joseph Mara, Jr. (CFO), Jonathan Siegal (Vice President & Corporate Controller), Paul Wotton (Director), and Robert Zerbe (Chairman & Director). Learn More on Vericel's active insiders.
Are insiders buying or selling shares of Vericel?: During the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 159,649 shares worth more than $7,655,811.79. The most recent insider tranaction occured on March, 13th when CEO Dominick Colangelo sold 26,592 shares worth more than $1,217,381.76. Insiders at Vericel own 5.2% of the company. Learn More about insider trades at Vericel.
Information on this page was last updated on 3/13/2025.

Paul K. Wotton Insider Trading History at Vericel

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2024	Sell	2,600	$58.72	$152,672.00	27,402
5/14/2021	Sell	5,000	$50.52	$252,600.00	26,602
5/11/2021	Sell	13,448	$50.11	$673,879.28	21,000
1/2/2019	Sell	22,500	$16.83	$378,675.00	5,000
6/18/2018	Sell	30,000	$12.06	$361,800.00	5,000

Paul K. Wotton Buying and Selling Activity at Vericel

Vericel Company Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $44.50

$44.10

$46.10

50 Day Range

MA: $53.23

$44.50

$61.80

2 Week Range

Now: $44.50

$39.12

$63.00

Volume

298,050 shs

Average Volume

377,899 shs

Market Capitalization

$2.23 billion

P/E Ratio

741.79

Dividend Yield

N/A

Beta

1.78